4-(3-methoxybenzyloxy)benzenamine | 937607-42-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-(3-methoxybenzyloxy)benzenamine
• 英文别名: 4-[(3-Methoxybenzyl)oxy]aniline；4-[(3-methoxyphenyl)methoxy]aniline
• CAS: 937607-42-6
• 化学式: C₁₄H₁₅NO₂
• mdl: MFCD08699255
• 分子量: 229.279
• InChiKey: ARRVSHHVHZSHQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3-methoxybenzyloxy)benzenamine 在 溶剂黄146 作用下， 以 乙醇 为溶剂， 生成 2-amino-4-((4-(3-methoxybenzyl)oxyphenyl)amino)-9H-pyrimido-[4,5-b]indol-6-ol
  参考文献：
  名称：

  Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance

  摘要：

  With ongoing resistance problems against the marketed EGFR inhibitors having a quinazoline core scaffold there is a need for the development of novel inhibitors having a modified scaffold and, thus, expected lower EGFR resistance problems. An additional problem concerning EGFR inhibitor resistance is an observed heterodimerization of EGFR with PDGFR-beta that neutralises the sole inhibitor activity towards EGFR. We developed novel pyrimido[4,5-b] indoles with varied substitution patterns at the 4-anilino residue to evaluate their EGFR and PDGFR-beta inhibiting properties. We identified dual inhibitors of both EGFR and PDGFR-beta in the nanomolar range which have been initially screened in cancer cell lines to prove a benefit of both EGFR and PDGFR-beta inhibition.

  DOI：

  10.1080/14756366.2017.1370583
• 作为产物：
  描述：

  3-methoxybenzyl 4-nitrophenyl ether 在 铁粉 、 氯化铵 作用下， 以 乙醇 、 水 为溶剂， 生成 4-(3-methoxybenzyloxy)benzenamine
  参考文献：
  名称：

  天然产物新pelolide作为细胞色素bc 1复合抑制剂：作用机理和结构修饰。

  摘要：

  从天然新科科动物的深水海绵标本中分离出海洋天然产物新科植物内酯。新pelolide已被证明是线粒体呼吸链中细胞色素bc 1复合物的新型抑制剂。然而，其详细的抑制机制仍是未知的。另外，由于新鸟苷内酯的化学结构非常复杂，因此很难合成。在当前的工作中，通过结合分子对接，分子动力学模拟和分子力学泊松-玻尔兹曼表面积计算，首次确定了新去内酯的结合模式，这表明新去内酯是bc 1的Q o抑制剂。复杂的。然后，根据抑制剂-蛋白质相互作用分析的指导，进行了结构修饰，目的在于简化新pelolide的化学结构，从而合成了一系列具有更简单化学结构的新neopeltolide衍生物。计算出的新合成类似物的结合能（ΔG cal）与它们的实验结合自由能（ΔG exp）具有很好的相关性（R 2 = 0.90 ），这证实了该计算方案是可靠的。具有二苯醚片段的化合物45已成功设计并合成为最有效的候选物（IC 50（＝ 12n

  DOI：

  10.1021/acs.jafc.8b06195

文献信息

• CYANOQUINOLINE DERIVATIVES
  申请人：Zhang Hesheng

  公开号：US20130225579A1

  公开（公告）日：2013-08-29

  Disclosed is a compound of formula I, a stereoisomer thereof, a cis-trans-isomer thereof, a tautomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, a solvate thereof or a prodrug thereof, wherein R 1 , R 2 , R 3 and R 4 are each as defined in the present application.

  公开了一种公式I的化合物，其立体异构体，其顺反异构体，其互变异构体，或它们的混合物，或其药物可接受的盐，其溶剂化物或其前药，其中R1，R2，R3和R4各自如在本申请中定义。
• Design, synthesis, and biological evaluation of N-(4-substituted)-3-phenylisoxazolo[5,4–d]pyrimidin-4-amine derivatives as apoptosis-inducing cytotoxic agents
  作者：Nikhil Baliram Gaikwad、Sapana Bansod、Alekhya Mara、Ramana Garise、Nanduri Srinivas、Chandraiah Godugu、Venkata Madhavi Yaddanapudi

  DOI：10.1016/j.bmcl.2021.128294

  日期：2021.10

  incorporating the important pharmacophoric features of 4-aminopyrimidine and phenyl isoxazole scaffold which is renowned for its BET inhibition activity. The designed molecules were synthesized and evaluated with the NCI-60 cell line panel. Examination by NCI-60 cell lines at single-dose and the five-dose study showed that compound 10h exhibited promising growth inhibitory effects with GI50 values on

  新的3 phenylisoxazolo [5,4的文库d ]嘧啶（8 - 10）的基于结合有重要的药效的支架杂交技术设计设有4氨基嘧啶和苯基异恶唑骨架，其以其BET抑制活性。设计的分子是用 NCI-60 细胞系面板合成和评估的。NCI-60 细胞系在单剂量和五剂量研究中的检查表明，化合物10h与 GI 50表现出有希望的生长抑制作用各种癌细胞系的值，例如 HCT-15（结肠癌）-0.0221 μM、MDA-MB-435（黑色素瘤）- 0.0318 μM、SNB-75（CNS 癌）-0.0263 μM 和 MCF7（乳腺癌）-0.0372微米。基于相差显微评估、DAPI、吖啶橙/溴化乙锭 (AO/EB) 染色和膜联蛋白 V-FITC 测定的进一步研究以了解10 小时的作用机制表明，细胞内 ROS 的升高导致线粒体膜电位反过来诱导 BT-474 癌细胞凋亡，这可能是化合物10h的合理作用机制。
• Synthesis and Anticancer Evaluation of 4-Anilinoquinolinylchalcone Derivatives
  作者：Cheng-Yao Yang、Min-Yu Lee、Yeh-Long Chen、Jun-Ping Shiau、Yung-Hsiang Tsai、Chia-Ning Yang、Hsueh-Wei Chang、Chih-Hua Tseng

  DOI：10.3390/ijms24076034

  日期：——

  A series of 4-anilinoquinolinylchalcone derivatives were synthesized and evaluated for antiproliferative activities against the growth of human cancer cell lines (Huh-7 and MDA-MB-231) and normal lung cells (MRC-5). The results exhibited low cytotoxicity against human lung cells (MRC-5). Among them, (E)-3-4-[4-(benzyloxy)phenyl]amino}quinolin-2-yl}-1-(4-methoxyphenyl) prop-2-en-1-one (4a) was found to have the highest cytotoxicity in breast cancer cells and low cytotoxicity in normal cells. Compound 4a causes ATP depletion and apoptosis of breast cancer MDA-MB-231 cells and triggers reactive oxygen species (ROS)-dependent caspase 3/7 activation. In conclusion, it is worth studying 4-anilinoquinolinylchalcone derivatives further as new potential anticancer agents for the treatment of human cancers.

  研究人员合成了一系列 4-苯胺基喹啉查尔酮衍生物，并评估了它们对人类癌细胞株（Huh-7 和 MDA-MB-231）和正常肺细胞（MRC-5）生长的抗增殖活性。结果表明，这些化合物对人肺部细胞（MRC-5）的细胞毒性较低。其中，(E)-3-4-[4-（苄氧基）苯基]氨基}喹啉-2-基}-1-（4-甲氧基苯基）丙-2-烯-1-酮（4a）对乳腺癌细胞的细胞毒性最高，而对正常细胞的细胞毒性较低。化合物 4a 会导致 ATP 耗竭和乳腺癌 MDA-MB-231 细胞凋亡，并引发活性氧（ROS）依赖性 caspase 3/7 激活。总之，4-苯胺基喹啉查尔酮衍生物作为治疗人类癌症的潜在抗癌新药值得进一步研究。
• OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF
  申请人：Beijing Scitech-MQ Pharmaceuticals Limited

  公开号：EP3760633A1

  公开（公告）日：2021-01-06

  Provided are an oxazino-quinazoline and oxazino-quinazoline type compound, a preparation method therefor, and uses thereof. More particularly provided is a compound shown in formula (I), an isomer, a hydrate, a solvate, a pharmaceutically acceptable salt, a prodrug thereof, a preparation method therefor, and uses thereof in preparing a drug acting as a kinase inhibitor.

  本发明提供了一种噁唑喹唑啉和噁唑喹唑啉类化合物、其制备方法及其用途。更具体地说，提供了一种式（I）所示的化合物、其异构体、水合物、溶质、药学上可接受的盐、原药、其制备方法以及其在制备作为激酶抑制剂的药物中的用途。
• Cyanoquinoline derivatives
  申请人：Tianjin Hemay Oncoloy Pharmaceutical Co., Ltd.

  公开号：US10246443B2

  公开（公告）日：2019-04-02

  Disclosed is a compound of formula I, a stereoisomer thereof, a cis-trans-isomer thereof, a tautomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, a solvate thereof or a prodrug thereof, wherein R1, R2, R3 and R4 are each as defined in the present application.

  公开了一种式 I 的化合物、其立体异构体、顺反异构体、同系物或其混合物，或其药学上可接受的盐、溶液或原药、 其中 R1、R2、R3 和 R4 各如本申请中所定义。